Jin Rong Jie·2025-06-03 10:54Core Viewpoint - Junshi Bioscience's stock closed at 33.06 yuan, up 1.69%, with a market-to-book ratio of 5.80, marking a new low in 157 days, and a total market capitalization of 32.587 billion yuan [1] Company Overview - Junshi Bioscience focuses on the research and development of new drugs, as well as the transfer and service of related technologies, including the production and sales of new drugs [1] - The company has 175 authorized patents, with 129 domestic and 46 international patents, covering various aspects of new drug protein structures, preparation processes, uses, and formulation recipes [1] Financial Performance - For Q1 2025, the company reported revenue of 501 million yuan, a year-on-year increase of 31.46%, while net profit was -234.88 million yuan, a year-on-year decrease of 17.01%, with a gross profit margin of 81.24% [2] Market Comparison - Junshi Bioscience's PE (TTM) is -26.43, with a static PE of -25.44 and a market-to-book ratio of 5.80, compared to the industry average PE of 64.63 and a market-to-book ratio of 10.39 [3] - The total market capitalization of Junshi Bioscience is 32.587 billion yuan, which is significantly lower than the industry median market capitalization of 80.24 billion yuan [3]